XAIR | Beyond Air, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.4151 - 0.4299
52 Week Range	0.3560 - 3.08
Beta	0.11
Implied Volatility	347.66%
IV Rank	100.00%
Day's Volume	76,932
Average Volume	846,014
Shares Outstanding	46,520,500
Market Cap	19,445,569
Sector	Healthcare
Industry	Medical - Devices
IPO Date	2018-06-12

Valuation
Profitability
Growth
Health
P/E Ratio	-0.25
Forward P/E Ratio	N/A
EPS	-1.64
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	107
Country	USA
Website	XAIR

Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

XAIR's peers: LUCD, NMTC, NARI, PAVMZ, CLPT, TBIO, RCEL, SGHT, TMCI, CTKB, HSKA, KIDS, ELMD, LUNG, TELA, CVRX, NPCE, TMDX, DCTH

*Chart delayed

Analyzing fundamentals for XAIR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see XAIR Fundamentals page.

Watching at XAIR technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on XAIR Technicals page.